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Scientific Note
J. Watson, co-discoverer of the double helix structure of the
DNA and a major force in cancer research over the last half
century, has sharply criticized the War on Cancer on the
following grounds: “Although the mortality from many can-
cers, particularly those of hematopoietic cells, has been stea-
dily falling, the more important statistic may be that so many
epithelial cancers (carcinomas) and effectively all mesen-
chymal cancers (sarcomas) remain largely incurable” 1. Thus,
Watson believes, that “the cancer world is not trying to cure
incurable cancer. They need to concentrate on late-state
disease ” 1-2.
Indeed, efforts to increase awareness and screening have
aimed to reduce late-stage disease and mortality. However,
data show a significant increase in early-stages without a
proportional decline in later ones 3. Fortunately, most can-
cers do not progress to death. Still, cancer takes a heavy toll
on society in terms of patient and family suffering, lost
productivity and ever straining demands on public and per-
sonal finances. In this context, made worse by a “tsunami” of
baby-boomers demanding more healthcare,4 laser photobi-
omodulation (L-PBM), alone or combined with standard
agents, may prove effective at targeting advanced cancer and
other complex diseases safely and, potentially, at a low cost.
A major obstacle for many cancer drugs aiming at single
molecular targets to minimizing nonspecific toxicity has
been that clinical response is often transitory and followed
by relapse 5. In light of this, and given that the acquisition of
new-generation cancer hallmarks is intricately linked and
made possible by the tumor microenvironment, it has been
suggested that new anticancer therapies should not aim at
single molecular targets to solely kill cancer cells, but at
re-establishing homeostasis-homeokinesis, a mi-
cro-environment effect which, as will be discussed below,
may be induced by light 6 .
L-PBM, also known as low-energy laser therapy (LLLT),
refers to the use of monochromatic or quasi-monochromatic
low-fluence light to induce primarily non-thermal photo-
chemical effects. Skepticism surrounding this multidiscipli-
nary field has been primordially rooted in a deep belief that,
to affect biological systems, electromagnetic signals must
ionize matter, or that too weak a signal may not be able to
trigger biological effects7. Thus, a poor understanding of the
physico-chemical basis of low-energy radiation and the fact
that much initial research was methodologically flawed and
came from behind the former Iron Wall deterred interest in
the West for decades 8 .
More than three hundred worldwide publications in reputed
peer reviewed journals have turned this scenario.  It has
been demonstrated that L-PBM can stimulate or inhibit cel-
lular function9.  It has also been ascertained that signal and
target characteristics determine biological outcome, which is
optimal (or even positive) only within a narrow set of para-
meters. Nonetheless, until recently, there was great trepida-
tion to explore L-PBM in cancer due to fear of increasing
tumor cell proliferation10-11.
Notwithstanding this, in cooperation with national and for-
eign research centers, our group completed animal testing
and embarked on a phase I clinical trial in patients with ad-
vanced and progressive neoplasias using a singular
low-energy infrared pulsed laser device (IPLD) that com-
bines high-frequency ultrasound and near-infrared (NIR)
radiation. Recruited patients, who suffered from advanced
Corresponding author: Luis Santana-Blank, MD;Fundalas Calle
Las Flores con Guaraguao, C.C. Carabel PB Local 2, MUN 1262.
Puerto La Cruz, Anzoátegui, Venezuela 6023-5; Email:
luissantanablank@msn.com
Int J Cancer Ther Oncol, Vol. 1, No. 1, pp. 6-8, 2013.
This is an open access article distributed under the terms of the
Creative Commons Attribution 3.0 License, which permits
unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Laser photobiomodulation: A new promising player for
the multi-hallmark treatment of advanced cancer
7 Santana-Blank et al.: Photobiomodulation for advanced cancer International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Santana-Blank et al. ISSN 2330-4049
solid tumors, including epithelial cancers (carcinomas) and
mesenchymal cancers (sarcomas), had exhausted available
treatment alternatives and had a life expectancy ≥ 12 weeks
(TNM IV- UICC).
After > 10 years of follow-up, the IPLD was found to be
clinically safe and to improve performance status and quality
of life. Antitumor activity was found in 88.23% of patients12.
Immune data from the same trial showed modulation of CD4
CD45RA+, CD25, TNF-alpha, and soluble IL-2 receptor
(sIL-2R),13 in agreement with Coussens and others14. Also
in accord with subsequent results by Tanaka et al., 15 the
cytomorphology results of the trial showed selective activa-
tion of programmed cellular death (i.e., apoptosis, necrosis,
anoikis ) in neoplastic cells, but not in peripheral tissues.
Microdensitometric T2-weighted MRI data further showed
increased water content in tumor heterogeneities preceding
tumor-volume reduction and therapeutic anticancer ef-
fects,16 showing that changes in water-content acted as early
predicator of tumor response in a manner consistent with
the approach of Ross, Chenevert and others 17-18 for early
tumor response determination.
Other studies show that L-PBM can trigger regenerative
responses, alone or associated with stem cell therapy19. Epi-
genetic modulate chromatin structure, which affects gene
transcription, 20 and L-PBM has been shown to reduce the
frequency of chromosome aberrations21. Clinical results fur-
ther suggest that L-PBM can cause phenotypic changes 22
consistent with theoretical data from a nonlinear DNA mod-
el, in which chaotic behaviors generated by damping, exter-
nal fields and torque in solitone dynamics induce open states
of the DNA which can regulate transcription and replica-
tion23. L-PBM has also shown effectiveness in the manage-
ment of radiotherapy complications, such as mucositis 24.
Structural, kinetic, and thermodynamic implications of the
above findings have been documented by our group25-27.  In
addition, we have proposed detailed mechanisms that com-
plement the work of numerous authors, 28-30 and which help
explain and substantiate one basic premise: that external
electromagnetic energy (light) supplementation can enhance
and even substitute for endogenous ATP production to pow-
er and modulate physiologically reparative mechanisms
which can help reestablish homeostasis-homeokynesis, even
when physiologic metabolic pathways have been compro-
mised 31.
Recently, based on studies by Pollack and others on the ex-
clusion zone (EZ), described as a fourth phase of water,32
we hypothesized that the EZ might be targeted by L-PBM as
an energy reservoir, which cells may use to fuel cellular
work and trigger signaling pathways and gene expression in
the presence of injury-induced redox potentials 31. Never-
theless, we stressed that experimental proof that L-PBM
would express effects via the EZ in a high-order biological
system had not been attained. Now, clinical and experimen-
tal results which are remarkably consistent with the current
understanding of the EZ are in press33. Such evidence, and
the growing substantiation and reproduction of the above
results, lead us to be confident that L-PBM will have a bright
future in medicine at large, and oncology in particular.
A major goal for L-PBM in cancer is to safely control pro-
grammed cellular death and differentiation, as suggested by
referred studies and in accord with the need for new mul-
tiple-hallmark cancer therapies. Challenges include deter-
mining optimal treatment parameters and further docu-
menting the underlying mechanisms for potential applica-
tions in oncology. However, and given that laser-based
technologies can be significantly less expensive than most
cancer drugs, we hope that L-PBM may soon help to lower
treatment costs whilst raising standard of care and quality of
life, particularly, for the most vulnerable, such as the elderly,
the poor and those suffering currently-untreatable late stage
disease.
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